MeiraGTx (MGTX) Revenue & Revenue Breakdown
MeiraGTx Revenue Highlights
Latest Revenue (Y)
$14.02M
Latest Revenue (Q)
$282.00K
MeiraGTx Revenue by Period
MeiraGTx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $14.02M | -11.95% |
| 2022-12-31 | $15.92M | -57.77% |
| 2021-12-31 | $37.70M | 142.25% |
| 2020-12-31 | $15.56M | 17.09% |
| 2019-12-31 | $13.29M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
MeiraGTx generated $14.02M in revenue during NA 2023, up -11.95% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
MeiraGTx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $282.00K | -59.54% |
| 2024-03-31 | $697.00K | -65.83% |
| 2023-12-31 | $2.04M | -60.02% |
| 2023-09-30 | $5.10M | 44.15% |
| 2023-06-30 | $3.54M | 6.18% |
| 2023-03-31 | $3.33M | -163.05% |
| 2022-12-31 | $-5.29M | -209.80% |
| 2022-09-30 | $4.82M | -55.24% |
| 2022-06-30 | $10.76M | 91.00% |
| 2022-03-31 | $5.63M | -73.23% |
| 2021-12-31 | $21.04M | 202.91% |
| 2021-09-30 | $6.95M | 35.79% |
| 2021-06-30 | $5.12M | 11.34% |
| 2021-03-31 | $4.59M | 21.31% |
| 2020-12-31 | $3.79M | -25.61% |
| 2020-09-30 | $5.09M | 105.84% |
| 2020-06-30 | $2.47M | -41.24% |
| 2020-03-31 | $4.21M | -39.37% |
| 2019-12-31 | $6.94M | 93.79% |
| 2019-09-30 | $3.58M | 80.79% |
| 2019-06-30 | $1.98M | 152.46% |
| 2019-03-31 | $784.96K | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
MeiraGTx generated $282.00K in revenue during Q2 2024, up -59.54% compared to the previous quarter, and up 8.46% compared to the same period a year ago.
MeiraGTx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals | $77.43M | $25.97M |
| ETON | Eton Pharmaceuticals | $31.64M | $9.07M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| QURE | uniQure | $15.84M | $11.13M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| CCCC | C4 Therapeutics | - | - |
| CNTB | Connect Biopharma | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| ERAS | Erasca | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| SLDB | Solid Biosciences | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| ELDN | Eledon Pharmaceuticals | - | - |
MGTX Revenue FAQ
What is MeiraGTx’s yearly revenue?
MeiraGTx's yearly revenue for 2023 was $14.02M, representing a decrease of -11.95% compared to 2022. The company's yearly revenue for 2022 was $15.92M, representing a decrease of -57.77% compared to 2021. MGTX's yearly revenue for 2021 was $37.7M, representing an increase of 142.25% compared to 2020.
What is MeiraGTx’s quarterly revenue?
MeiraGTx's quarterly revenue for Q2 2024 was $282K, a -59.54% decrease from the previous quarter (Q1 2024), and a -92.03% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $697K, a -65.83% decrease from the previous quarter (Q4 2023), and a -79.09% decrease year-over-year (Q1 2023). MGTX's quarterly revenue for Q4 2023 was $2.04M, a -60.02% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is MeiraGTx’s revenue growth rate?
MeiraGTx's revenue growth rate for the last 3 years (2021-2023) was -62.82%, and for the last 5 years (2019-2023) was 5.45%.